Navigation Links
ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
Date:7/1/2008

IRVINE, Calif., July 1 /PRNewswire/ -- ChromaDex, Inc. ("ChromaDex"), today announced that effective June 20, 2008, it completed its merger with CDI Acquisition, Inc. ("CDI"), the wholly-owned subsidiary of Cody Resources, Inc. ("Cody") (OTC Bulletin Board: CDYE). The transaction enables ChromaDex to be wholly owned by a company whose shares are publicly traded, which will help it be better positioned to meet the ongoing needs of a rapidly growing marketplace. The business and operations of ChromaDex prior to the merger continue unchanged after the merger, and ChromaDex should continue to meet demand for analytical tools, products, and services that help customers comply with regulatory, quality, efficacy and safety standards for their products.

The merger was completed pursuant to an Agreement and Plan of Merger dated May 21, 2008, by and among ChromaDex, Cody and CDI. As a result of the merger, ChromaDex became a wholly owned subsidiary of Cody, each outstanding share of ChromaDex common stock automatically converted into the right to receive one share of common stock of Cody and ChromaDex shareholders own or have the right to own, in the aggregate, approximately 23,522,122 shares, or 84% of the outstanding common stock of Cody. Also in connection with the Merger, Cody changed its state of incorporation from Nevada to Delaware and changed its name to ChromaDex Corporation.

"We are pleased to have completed this reverse merger as a means of achieving public ownership for ChromaDex," said Frank Jaksch, CEO and co-founder of ChromaDex. "This merger into the public arena affords ChromaDex benefits of public ownership, including the ability to enhance our visibility with customers and prospective customers, additional liquidity for existing and future equity investors, and access to potential additional avenues for capital formation to help us grow and expand to meet the needs of the sizable natural product chemistry, dietary supplement, functional food, cosmetic and pharmaceutical marketplaces with our unique skill set and value proposition. We believe this merger provides ChromaDex with a foundation for new opportunities to better meet the needs of the customer as well as the benefits of an ongoing public market valuation."

About ChromaDex

ChromaDex is a world leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable, "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools, products, and services to meet the regulatory, quality, efficacy and safety standards for their products.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.


'/>"/>
SOURCE ChromaDex
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):